安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AMGN 安进

未开盘 10-02 16:00:00 EDT

403.04

-4.23

-1.04%

盘后404.00

+0.96+0.24%

19:58 EDT

最高410.16	最低401.96	成交量351.03万
今开410.16	昨收407.27	日振幅2.01%
总市值2,170亿	流通市值2,164亿	总股本5.38亿
成交额14.16亿	换手率0.65%	流通股本5.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AMGN","market":"US","secType":"STK","nameCN":"安进","latestPrice":403.04,"timestamp":1790971200000,"preClose":407.27,"halted":0,"volume":3510302,"hourTrading":{"tag":"盘后","latestPrice":404,"preClose":403.04,"latestTime":"19:58 EDT","volume":1273609,"amount":513315949.649001,"timestamp":1790985513505,"change":0.96,"changeRate":0.002382,"amplitude":0.003573},"delay":0,"changeRate":-0.010386230264934715,"floatShares":536994627,"shares":538480671,"eps":16.1,"marketStatus":"未开盘","change":-4.23,"latestTime":"10-02 16:00:00 EDT","open":410.16,"high":410.16,"low":401.96,"amount":1416310885.3433201,"amplitude":0.020134,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":16.1,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":423288000000,"exchange":"NASDAQ","adjPreClose":407.27,"dividendRate":0.024315,"preHourTrading":{"tag":"盘前","latestPrice":409.1,"preClose":407.27,"latestTime":"09:29 EDT","volume":4595,"amount":1883487.9268,"timestamp":1790947799999,"change":1.83,"changeRate":0.004493,"amplitude":0.05446},"postHourTrading":{"tag":"盘后","latestPrice":404,"preClose":403.04,"latestTime":"19:58 EDT","volume":1273609,"amount":513315949.649001,"timestamp":1790985513505,"change":0.96,"changeRate":0.002382,"amplitude":0.003573},"volumeRatio":1.2103254548097357,"impliedVol":0.3127,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/AMGN","defaultTab":"news","newsList":[{"id":"2669453169","title":"安进一种自身免疫药物在后期临床试验达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2669453169","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669453169?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:32","pubTimestamp":1790217159,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0889565916.HKD","LU0058720904.USD","BK4566","LU2242646821.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","LU0109394709.USD","IBB","SG9999001440.SGD","BK4139","AMGN","BK4581","LU1023059063.AUD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU2112291526.USD","TBXU","BK4533","LU0868494617.USD","BMED","LU2089984988.USD","LU1571399168.USD","IBBQ","LU0122379950.USD","BIB","IE00BFTCPJ56.SGD","BK4534","BK4599","LU0289739699.SGD","IE0009355771.USD","MDTX","PJP","PSYK","BK4588","IBBJ","IE00B2B36J28.USD","LU1061106388.HKD","PBE","BBH","BK4585","LU1057294990.SGD","LU2242652126.USD","LU1983299246.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121969920","title":"安进宣布Dazodalibep在干燥综合征III期试验中达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1121969920","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121969920?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:50","pubTimestamp":1790085037,"startTime":"0","endTime":"0","summary":"路透社9月22日消息——安进公司（Amgen Inc）于近日披露其关键临床进展：\n安进旗下药物Dazodalibep在针对中重度症状性干燥综合征的III期OASIZ 303研究中，成功达到主要终点，该项试验预计将于2026年第四季度完成。\n安进表示，Dazodalibep在III期干燥综合征试验中取得主要终点的积极结果，该药物在系统性疾活动度方面展现出具有统计学显著性及临床意义的改善。\n值得注意的是，这一进展为干燥综合征患者群体带来了新的治疗希望。安进公司股票代码为AMGN.O。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B2B36J28.USD","LU0889565916.HKD","LU0289739699.SGD","LU0868494617.USD","LU2112291526.USD","AMGN","LU1571399168.USD","BBH","BK4588","LU0109394709.USD","LU2242646821.SGD","LU2242652126.USD","LU2468319806.SGD","LU1023059063.AUD","BK4585","LU0122379950.USD","LU1983299246.USD","IBB","PJP","BIB","BK4533","TBXU","IBBQ","LU1057294990.SGD","BK4581","IE0009355771.USD","IE0002141913.USD","LU0058720904.USD","LU1061106388.HKD","LU0320765992.SGD","SG9999001440.SGD","IE00BJT1NW94.SGD","BK4534","LU2089984988.USD","PBE","IE00BJJMRZ35.SGD","BK4566","BK4599","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155863448","title":"异动解读｜安进盘中上涨3.39%，Dazodalibep三期临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1155863448","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155863448?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:38","pubTimestamp":1790084313,"startTime":"0","endTime":"0","summary":"9月22日，安进盘中上涨3.39%，报406.375美元/股，成交额1.92亿美元。消息面上，安进宣布其研发的Dazodalibep在针对中重度系统性干燥综合征的3期临床试验中取得积极顶线结果，与安慰剂组相比，接受该药物治疗的患者在系统性疾病活动指标上实现了统计学显著且具有临床意义的改善。此外，安进近期研发管线利好密集，此前其Imdelltra联合阿斯利康英飞凡在广泛期小细胞肺癌III期试验中达成总生存期主要终点，FDA亦批准缩短Imdelltra前两剂监测时间，研发动能持续增强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"安进盘中上涨，Dazodalibep三期临床报捷","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114208","title":"安进股价盘前大涨逾4%，受第三期临床试验结果提振。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669114208?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:07","pubTimestamp":1790082475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2242646821.SGD","MRNY","IDNA","BK4599","MEDI","PSCH","TMED","IEIH","BIB","BBH","FBT","BME","FTXH","BK4585","PBE","GNOM","LU2272731865.HKD","LFSC","PJP","SYNB","AMGN","CANC","RXL","HELX","IE00B5TLWC47.USD","IBRN","IEHS","PPH","TBXU","IBB","IE00B4R5TH58.HKD","LU2272731782.SGD","BIOY","IYH","BBP","IBBQ","LU2473716301.USD","AZNH","XPH","LU0122379950.USD","LU0320765992.SGD","SBIO","RSPH","XBIX","MRNX","LU1992135472.HKD","PBPH","WDNA","LU0058720904.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136650653","title":"异动解读｜安进盘前上涨4.79%，Dazodalibep三期临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136650653","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136650653?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:05","pubTimestamp":1790082316,"startTime":"0","endTime":"0","summary":"9月22日，安进盘前上涨4.79%，报412.0美元/股，成交额727.28万美元。消息面上，安进宣布其研发的Dazodalibep在针对中重度系统性干燥综合征的3期临床试验中取得积极顶线结果，与安慰剂组相比，接受该药物治疗的患者在系统性疾病活动指标上实现了统计学显著且具有临床意义的改善。此外，安进近期管线利好频传，此前其Imdelltra联合阿斯利康英飞凡在广泛期小细胞肺癌III期试验中也达成总生存期主要终点，研发动能持续增强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"安进盘前上涨，干燥综合征新药三期告捷","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167058424","title":"安进宣布Dazodalibep治疗中重度系统性干燥综合征的3期临床试验取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1167058424","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167058424?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:04","pubTimestamp":1790082253,"startTime":"0","endTime":"0","summary":"安进公司今日发布重磅消息：其研发的Dazodalibep在针对中重度系统性干燥综合征的3期临床试验中，交出了一份令人振奋的答卷。这项研究聚焦于那些饱受病痛折磨的患者群体，而试验数据无疑为这片治疗荒漠带来了希望的甘霖。结果显示，与安慰剂组相比，接受Dazodalibep治疗的患者在关键疗效指标上均实现了统计学意义上的显著改善。分析人士指出，该药物的成功若能在后续环节得以延续，其市场潜力不容小觑，或将重新定义干燥综合征的治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4139","LU0289739699.SGD","LU0109394709.USD","LU1061106388.HKD","LU2242652126.USD","BBH","LU0122379950.USD","BK4599","PBE","IBBQ","LU2089984988.USD","AMGN","LU0889565916.HKD","LU1571399168.USD","BK4566","IE00BJT1NW94.SGD","BIB","BK4588","LU2242646821.SGD","PJP","LU0868494617.USD","IE0002141913.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","TBXU","BK4533","LU0320765992.SGD","LU1023059063.AUD","IBB","IE0009355771.USD","LU1983299246.USD","BK4585","BK4581","LU2112291526.USD","SG9999001440.SGD","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196869155","title":"安进：Dazodalibep在系统性疾病活动方面展现出统计学显著且具有临床意义的改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1196869155","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196869155?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:01","pubTimestamp":1790082073,"startTime":"0","endTime":"0","summary":"安进公司宣布，其实验性药物Dazodalibep在治疗中取得了重大突破。最新研究数据显示，该药物在改善系统性疾病活动方面，不仅达到了统计学上的显著效果，更在临床实践中展现出切实的改善意义。\n这一积极结果无疑为患者群体带来了新的希望，同时也为安进在竞争激烈的医药研发领域增添了重要砝码。相关研究的具体数据与详细分析，预计将在后续的医学会议或学术期刊中进一步披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","TBXU","LU2468319806.SGD","IE00BJT1NW94.SGD","PBE","LU1057294990.SGD","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD","LU1571399168.USD","IE0009355771.USD","BK4599","LU0868494617.USD","BK4533","BK4585","AMGN","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","LU2112291526.USD","LU0289739699.SGD","LU0889565916.HKD","LU0122379950.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","PJP","BK4534","IBB","LU0058720904.USD","LU2242646821.SGD","BK4588","BK4581","BBH","BK4566","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144298886","title":"安进：Dazodalibep治疗中重度症状性干燥综合征的Oasiz 303三期研究预计2026年第四季度完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1144298886","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144298886?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:00","pubTimestamp":1790082009,"startTime":"0","endTime":"0","summary":"安进（Amgen）披露，其针对中重度症状性干燥综合征（Sjögren's Disease）所开展的Dazodalibep三期临床研究——即Oasiz 303试验，预计将于2026年第四季度圆满完成。这一时间表的明确，为该公司在自身免疫疾病领域的管线推进提供了新的节点参照。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU1023059063.AUD","LU0058720904.USD","LU2468319806.SGD","BK4533","IBBQ","IE0009355771.USD","LU2089984988.USD","BK4534","BIB","IE00BJT1NW94.SGD","LU2242646821.SGD","SG9999001440.SGD","LU1057294990.SGD","AMGN","LU0868494617.USD","LU1983299246.USD","BK4585","BK4581","IE0002141913.USD","PJP","IE00B4R5TH58.HKD","LU1061106388.HKD","LU0289739699.SGD","BBH","IE00B2B36J28.USD","LU0122379950.USD","TBXU","IBB","LU0109394709.USD","LU0889565916.HKD","LU2112291526.USD","BK4139","BK4588","LU1571399168.USD","LU2242652126.USD","BK4566","PBE","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667267605","title":"百时美施贵宝就安进拟推出的Opdivo生物类似药提起诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2667267605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667267605?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:15","pubTimestamp":1789524901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1236620834.HKD","LU1236620750.USD","IE00BSNM7G36.USD","LU0320765992.SGD","LU0114720955.EUR","BK4566","LU0868494617.USD","BBH","LU1883839398.USD","LU0225771236.USD","LU0061475181.USD","BIB","LU1983299246.USD","LU1989771016.USD","IBB","BK4585","XPH","BK4534","LU0225284248.USD","LU1261432733.SGD","LU0058720904.USD","BK4533","LU1868837300.USD","LU2272731600.USD","BK4559","BK4588","LU0289739699.SGD","LU2473716301.USD","LU2322448957.HKD","IE00B4R5TH58.HKD","AMGN","IE0009355771.USD","LU0109394709.USD","BMY","BK4139","LU2468319806.SGD","IHE","PJP","LU1868836757.USD","LU2125154778.USD","FTXH","TBXU","PBE","IBBQ","LU2272731865.HKD","LU1868836591.USD","LU1670711123.USD","LU1023059063.AUD","PPH","LU1992135399.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安进（AMGN）联合疗法III期临床达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666712586?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","PJP","IBB","LU2242646821.SGD","LU0889565916.HKD","LU2236285917.USD","IE00B2B36J28.USD","LU0109394709.USD","LU2468319806.SGD","LU2089984988.USD","AMGN","LU1571399168.USD","BBH","BK4139","LU0868494617.USD","TBXU","BK4581","LU0128525929.USD","IE0002141913.USD","LU2237443622.USD","LU2242652126.USD","LU2112291526.USD","BK4534","BK4568","SG9999001440.SGD","BK4599","LU0708994859.HKD","AZNH","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","PBE","LU0029864427.USD","LU1829250122.USD","BK4566","BK4533","LU0432979614.USD","LU2237443978.SGD","LU2462157665.USD","LU1023059063.AUD","LU2237443382.USD","LU0058720904.USD","LU0122379950.USD","IBBQ","LU1267930573.SGD","BIB","IE00B4R5TH58.HKD","LU0289739699.SGD","LU2456880835.USD","BK4585","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666730093","title":"诺华(NVS.US)心血管疗法试验“爆雷”拖累安进(AMGN.US)：股价暴跌创十年之最，BMO火速下调评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2666730093","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666730093?lang=zh_cn&edition=full","pubTime":"2026-09-09 14:43","pubTimestamp":1788936181,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，受诺华制药近日宣布其与Ionis Pharmaceuticals联合开发的一款心脏病疗法在后期临床试验中遭遇挫折影响，安进股价周二下跌超10%，创下自2016年以来最大单日跌幅。该药物由安进与Arrowhead Pharmaceuticals及Royalty Pharma合作开发，研究设计与此前试验相似。Skorney在报告中维持对安进的“跑赢大盘”评级，但坦言：“尽管两个项目之间存在关键差异，有可能助力安进最终成功，但我们认为更可能出现类似的不利结果。”他维持对安进450美元的目标价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AMGN","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安进-阿斯利康肺癌联合用药在后期临床试验中显著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666309213?lang=zh_cn&edition=full","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BBH","IE0002141913.USD","LU1057294990.SGD","LU0889565916.HKD","TBXU","BMED","BK4588","SG9999001440.SGD","LU1983299246.USD","LU0868494617.USD","PJP","PBE","IBBJ","BK4139","IE00BFTCPJ56.SGD","LU2112291526.USD","PSYK","IE00BJT1NW94.SGD","BK4566","LU0122379950.USD","BK4533","MDTX","LU1061106388.HKD","IBB","LU1023059063.AUD","LU2089984988.USD","BIB","AMGN","LU0058720904.USD","BK4534","BK4581","LU0320765992.SGD","IBBQ","LU2242646821.SGD","LU2468319806.SGD","LU1571399168.USD","IE0009355771.USD","LU0289739699.SGD","BK4585","BK4599","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市场风向标：安进股价遭受重创","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112638879?lang=zh_cn&edition=full","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"hk","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU1983299246.USD","IE00B2B36J28.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","AMGN","LU0058720904.USD","IE00BJT1NW94.SGD","BK4139","BK4599","IE0009355771.USD","LU2468319806.SGD","PJP","BBH","IBBQ","BK4534","LU0320765992.SGD","BK4581","LU0868494617.USD","LU1057294990.SGD","LU0122379950.USD","BIB","LU2242652126.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","BK4533","IE00BJJMRZ35.SGD","BK4585","LU0289739699.SGD","BK4588","LU2112291526.USD","IE0002141913.USD","BK4566","LU2089984988.USD","IBB","LU1023059063.AUD","TBXU","SG9999001440.SGD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安进股价或创二十余年来最大单日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111756325?lang=zh_cn&edition=full","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"hk","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","TBXU","LU2468319806.SGD","IE00BJT1NW94.SGD","PBE","LU1057294990.SGD","LU2089984988.USD","LU2242652126.USD","LU1061106388.HKD","LU1571399168.USD","IE0009355771.USD","BK4599","LU0868494617.USD","BK4533","BK4585","AMGN","BK4139","IE00BFTCPJ56.SGD","IBBQ","BIB","LU2112291526.USD","LU0289739699.SGD","LU0889565916.HKD","LU0122379950.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","PJP","BK4534","IBB","LU0058720904.USD","LU2242646821.SGD","BK4588","04332","BK4581","BBH","BK4566","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","LU0320765992.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375527","title":"安进股价下跌7%，创下自2025年6月以来最大单日跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665375527?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:30","pubTimestamp":1788874246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4534","IE00B4R5TH58.HKD","LU1057294990.SGD","BK4139","LU0289739699.SGD","LU0109394709.USD","LU1061106388.HKD","LU2242652126.USD","BBH","LU0122379950.USD","BK4599","PBE","IBBQ","LU2089984988.USD","AMGN","LU0889565916.HKD","LU1571399168.USD","BK4566","IE00BJT1NW94.SGD","BIB","BK4588","LU2242646821.SGD","PJP","LU0868494617.USD","IE0002141913.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","TBXU","BK4533","LU0320765992.SGD","LU1023059063.AUD","IBB","IE0009355771.USD","LU1983299246.USD","BK4585","BK4581","LU2112291526.USD","SG9999001440.SGD","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安进Phase 3 Dellphi-305研究重大突破：总生存期获益显著优于度伐利尤单抗单药治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115495471?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比，该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现，无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露，但安进方面表示，其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进，安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","SG9999001440.SGD","LU2112291526.USD","LU1571399168.USD","LU0889565916.HKD","BK4566","BBH","BK4139","BK4599","BK4534","LU0320765992.SGD","PBE","LU0058720904.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU1057294990.SGD","BK4581","IE0009355771.USD","AMGN","IE00B2B36J28.USD","LU2089984988.USD","BIB","IE00BJT1NW94.SGD","LU1983299246.USD","PJP","LU2242646821.SGD","IE0002141913.USD","LU0122379950.USD","BK4533","IBB","TBXU","IBBQ","LU2242652126.USD","BK4588","BK4585","LU0868494617.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","LU1023059063.AUD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®联合Imfinzi®在一线广泛期小细胞肺癌中展现里程碑式总生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109517247?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法，于一线广泛期小细胞肺癌治疗领域，取得了具有划时代意义的总生存期提升。这一突破性进展，不仅为患者带来了新的曙光，也重塑了该领域的治疗格局。从数据层面观察，联合治疗方案的生存获益尤为显著，堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","IBBQ","IE0009355771.USD","LU1023059063.AUD","BK4566","LU2242646821.SGD","PBE","IE00BJT1NW94.SGD","IBB","LU1061106388.HKD","SG9999001440.SGD","IE00BJJMRZ35.SGD","BK4533","LU0109394709.USD","BK4585","BK4139","LU1571399168.USD","BK4534","LU2089984988.USD","LU1057294990.SGD","LU0868494617.USD","LU0320765992.SGD","LU0058720904.USD","BK4581","BK4599","LU0889565916.HKD","IE00B2B36J28.USD","LU1983299246.USD","LU2112291526.USD","LU2242652126.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","PJP","IE00B4R5TH58.HKD","BK4588","LU0289739699.SGD","TBXU","BIB","BBH","AMGN","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665387373","title":"BMO下调安进及BioNTech评级至“与大市同步”","url":"https://stock-news.laohu8.com/highlight/detail?id=2665387373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665387373?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:59","pubTimestamp":1788872377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2089984988.USD","PBE","IE00BJJMRZ35.SGD","LU1061106388.HKD","BK4534","LU2112291526.USD","BK4588","BBH","IE0009355771.USD","LU2242652126.USD","TBXU","BK4581","BIB","BK4566","LU0109394709.USD","LU2242646821.SGD","BK4585","LU2468319806.SGD","IE00BJT1NW94.SGD","BK4139","IBB","LU0889565916.HKD","LU1983299246.USD","LU1057294990.SGD","PJP","LU0868494617.USD","IE00BFTCPJ56.SGD","IBBQ","LU0289739699.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","IE0002141913.USD","BK4533","SG9999001440.SGD","LU0058720904.USD","LU1023059063.AUD","LU1571399168.USD","BK4599","AMGN","IE00B2B36J28.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326953","title":"美股异动｜安进盘前跌5.4%，诺华同靶点药物III期临床失败，Lp(a)赛道遭重创","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326953","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665326953?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:07","pubTimestamp":1788858422,"startTime":"0","endTime":"0","summary":"消息面上，诺华于9月4日公布，其与Ionis联合开发的降脂药物Pelacarsen，在名为LpHORIZON的III期临床试验中未能达到主要终点。诺华的Pelacarsen是全球首个针对Lp靶点进行心血管结局验证的III期药物。因此，市场担忧情绪蔓延到了同样在开发Lp药物的安进身上。多家分析机构认为，诺华的失败削弱了但并未完全推翻Lp这一靶点的可行性。安进后续公布的Olpasiran完整试验数据，将成为判断该靶点未来走向的关键。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4566","IE0009355771.USD","LU2468319806.SGD","IBBQ","BK4585","LU0122379950.USD","IE00B2B36J28.USD","BK4588","BK4578","BK4533","BK4139","LU2089984988.USD","BK4534","LU1057294990.SGD","IE00BJJMRZ35.SGD","BK4007","BK4581","LU0320765489.SGD","BIB","TBXU","LU0320765992.SGD","MEDX","LU0058720904.USD","LU0889565916.HKD","BK4532","BBH","IBB","LU0211331839.USD","LU1023059063.AUD","IE00BFTCPJ56.SGD","LU0070302665.USD","IE0002141913.USD","LU1571399168.USD","IE00B4R5TH58.HKD","LU1061106388.HKD","LU0109394709.USD","LU0289739699.SGD","LU0868494617.USD","LU1983299246.USD","PPH","LU0208291251.USD","LU2242652126.USD","PJP","BK4599","SG9999001440.SGD","IE00BJT1NW94.SGD","NVS","AMGN","LU2112291526.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665258833","title":"安进股价盘前下跌5.4%；竞争对手诺华的胆固醇药物后期临床试验失败。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665258833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665258833?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:28","pubTimestamp":1788856084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0002141913.USD","IBBQ","BK4566","IE00BFTCPJ56.SGD","BK4599","LU2242652126.USD","MDTX","PBE","IE00BJJMRZ35.SGD","LU2468319806.SGD","BK4534","LU0289739699.SGD","IE00BJT1NW94.SGD","BIB","IBBJ","LU0320765992.SGD","LU0070302665.USD","AMGN","LU0122379950.USD","BK4578","BMED","LU0208291251.USD","LU0868494617.USD","BK4532","LU0211331839.USD","PJP","PSYK","BK4581","BK4533","NVS","IBB","PPH","LU1983299246.USD","TBXU","MEDX","BK4585","LU2242646821.SGD","BK4007","LU2112291526.USD","BK4588","LU0889565916.HKD","LU0109394709.USD","LU1061106388.HKD","LU0058720904.USD","LU2089984988.USD","BBH","SG9999001440.SGD","LU1023059063.AUD","LU1057294990.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amgen.com","stockEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.0899},{"period":"3month","weight":0.0772},{"period":"6month","weight":0.1584},{"period":"1year","weight":0.3552},{"period":"ytd","weight":0.2314}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1735},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.1286}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"安进公司于1980年在加利福尼亚成立，并于1987年成为特拉华州的一家公司。该公司发现、开发、制造和交付创新药物，以对抗世界上一些最棘手的疾病。该公司专注于高度未满足的医疗需求领域，并利用其专业知识努力寻求能够显著改善人们生活的解决方案，同时还能减轻疾病带来的社会和经济负担。该公司在40多年前帮助启动了生物技术产业，并已成长为世界领先的独立生物技术公司之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.651163,"avgChangeRate":0.034336},{"month":2,"riseRate":0.488372,"avgChangeRate":0.00202},{"month":3,"riseRate":0.511628,"avgChangeRate":0.016602},{"month":4,"riseRate":0.44186,"avgChangeRate":-0.003156},{"month":5,"riseRate":0.511628,"avgChangeRate":0.022981},{"month":6,"riseRate":0.511628,"avgChangeRate":0.005534},{"month":7,"riseRate":0.772727,"avgChangeRate":0.052813},{"month":8,"riseRate":0.613636,"avgChangeRate":0.006989},{"month":9,"riseRate":0.5,"avgChangeRate":0.001801},{"month":10,"riseRate":0.522727,"avgChangeRate":0.020053},{"month":11,"riseRate":0.627907,"avgChangeRate":0.022348},{"month":12,"riseRate":0.627907,"avgChangeRate":0.045446}],"exchange":"NASDAQ","name":"安进","nameEN":"Amgen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"安进,AMGN,安进股票,安进股票老虎,安进股票老虎国际,安进行情,安进股票行情,安进股价,安进股市,安进股票价格,安进股票交易,安进股票购买,安进股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"安进(AMGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供安进(AMGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}